Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental CAR-T therapy targets Hard-to-Treat blood cancer

NCT ID NCT07350863

Recruiting now Disease control Sponsor: The First Affiliated Hospital of Soochow University Source: ClinicalTrials.gov ↗

First seen Jan 23, 2026 · Last updated May 02, 2026 · Updated 17 times

Summary

This early-stage trial tests a new treatment called U69, which uses specially engineered immune cells (CAR-T cells) to find and attack cancer cells in patients with T-cell leukemia or lymphoma that has come back or not responded to standard treatments. The study aims to check the safety of different doses and find the best dose for future studies. About 12 to 18 participants aged 15 to 75 will be enrolled, and they will be followed for up to 2 years after treatment, with long-term monitoring for up to 15 years.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY T-LYMPHOBLASTIC LEUKEMIA/LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The First Affiliated Hospital of Soochow University

    RECRUITING

    Suzhou, Jiangsu, 215006, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

RELAPSED/REFRACTORY T-LYMPHOBLASTIC LEUKEMIA/LYMPHOMA